Pilot Neoadjuvant Trial with Combination of Lapatinib and Nab-Paclitaxel in HER2+Breast Cancer

被引：0
|
作者：
Kaklamani, V [1 ]
Uthe, R. [1 ]
Khan, S. [1 ]
Hansen, N. [1 ]
Bethke, K. [1 ]
Jeruss, J. [1 ]
Cianfrocca, M. [1 ]
Von Roenn, J. [1 ]
Rosen, S. [1 ]
Gradishar, W. [1 ]
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：568S / 568S
页数：1
相关论文
共 50 条
  • [31] Phase ib study of trastuzumab emtansine (TDM1) in combination with lapatinib and nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: Stela results
    Patel, Tejal Amary
    Ensor, Joe
    Rodriguez, Angel Augusto
    Belcheva, Anna
    Darcourt, Jorge German
    Niravath, Polly Ann
    Kuhn, John G.
    Kaklamani, Virginia G.
    Li, Xiaoxian
    Boone, Toniva
    Chang, Jenny Chee Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Soluble TNFα overcomes lapatinib resistance in HER2+breast cancer
    Bruni, Sofia
    Mauro, Florencia L.
    De Martino, Mara
    Deamicis, Agustina Roldan
    Mercogliano, Maria F.
    Schillaci, Roxana
    Elizalde, Patricia, V
    CANCER RESEARCH, 2020, 80 (16)
  • [33] A Phase II Study of Neoadjuvant PLD/Cyclophosphamide and Sequential nab-Paclitaxel Plus Dual HER2 Blockade in HER2-Positive Breast Cancer
    Yang, Ji-Xin
    Yang, Yu-Qing
    Hu, Wen-Yu
    Yang, Lu
    Wu, Jiang
    Wen, Xin-Xin
    Yu, Jing
    Huang, Mei-Ling
    Xu, Dong-Dong
    Tie, Dan-Chen
    Wang, Lei
    Li, Fan-Fan
    Li, Nan-Lin
    ONCOLOGIST, 2024, 29 (01): : e15 - e24
  • [34] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [35] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [36] A phase I study of romidepsin in combination with nab-paclitaxel in patients with metastatic HER-2 negative inflammatory breast cancer (IBC)
    Avery, T. P.
    Jaslow, R.
    Basu-Mallick, A.
    Zibelli, A.
    Fellin, F.
    Cristofanilli, M.
    CANCER RESEARCH, 2016, 76
  • [37] Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer
    Ogino, Misato
    Fujii, Takaaki
    Koibuchi, Yukio
    Nakazawa, Yuko
    Takata, Daisuke
    Shirabe, Ken
    ANTICANCER RESEARCH, 2021, 41 (08) : 3899 - 3904
  • [38] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines
    Tonissi, Federica
    Lattanzio, Laura
    Merlano, Marco C.
    Infante, Lucia
    Lo Nigro, Cristiana
    Garrone, Ornella
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (04) : 801 - 809
  • [40] The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines
    Federica Tonissi
    Laura Lattanzio
    Marco C. Merlano
    Lucia Infante
    Cristiana Lo Nigro
    Ornella Garrone
    Investigational New Drugs, 2015, 33 : 801 - 809
12345